Results 171 to 180 of about 210,707 (288)

The Shewanella oneidensis Fic enzyme SoFic targets the switch‐I region of EF‐Tu for AMPylation

FEBS Letters, EarlyView.
Fic enzymes mediate diverse post‐translational modifications across all domains of life, including AMPylation. Prokaryotic EF‐Tu can be AMPylated and deAMPylated by the conserved Fic enzyme SoFic. Structural and biochemical approaches were used to characterize the effect of AMPylation on EF‐Tu, SoFic's enzymatic activities, and the enzyme‐target ...
Svenja Runge, Vivian Pogenberg, Alexander Baumgart, Bente Siebels, Hartmut Schlüter, Michael Hecht‐Bucher, Aymelt Itzen   +6 more
wiley   +1 more source

Summary of Research: Aflibercept 8 mg versus Faricimab Treat‑and‑Extend for Diabetic Macular Edema or Neovascular Age‑Related Macular Degeneration: A Bayesian Fixed‑Effect Network Meta‑analysis of Clinical Trials. [PDF]

Ophthalmol Ther
Friedman SM, Xu Y, Sherman S, Kuznik A, Mojebi A, Keeping S, Chan K, Leng T, Patel NA.   +8 more
europepmc   +1 more source

Hypoglycaemic attacks treated by ambulance personnel with extended training. [PDF]

BMJ, 1990
C, Weston, M, Stephens
openaire   +2 more sources

Prospecting the protein design landscape

FEBS Letters, EarlyView.
This review outlines the current state of various protein design approaches. We discuss the current possibilities enabled by recently released tools, highlight future avenues to pursue in protein design, and underscore the crucial role of key databases and resources for successful protein design workflows.
Jakob R. Riccabona, Katharina T. Stonig, Jens Meiler, Clara T. Schoeder, Monica L. Fernández‐Quintero   +4 more
wiley   +1 more source

Letter to the Editor Regarding "Aflibercept 8 mg versus Faricimab Treat-and-Extend for Diabetic Macular Edema or Neovascular Age-Related Macular Degeneration: A Bayesian Fixed-Effect Network Meta-analysis of Clinical Trials". [PDF]

Ophthalmol Ther
Panos GD.
europepmc   +1 more source

Artificial molecular machines and motors—Design and control of nanoscale motion

FEBS Letters, EarlyView.
Molecules are constantly moving because of thermal fluctuations, but random motion alone cannot be exploited to perform directional tasks. Artificial molecular machines use chemical, electrical, or light energy to bias this motion. Molecular shuttles, rotary motors, and supramolecular pumps illustrate how nanoscale movement can be controlled and ...
Leonardo Andreoni, Alberto Credi
wiley   +1 more source

Aflibercept 8 mg treat-and-extend pathway for the treatment of neovascular age-related macular degeneration: guidance from a UK expert panel. [PDF]

Eye (Lond)
Gale R, Awad MH, Bailey C, Cackett P, Chhabra R, Downey L, Ghanchi F, Kotagiri A, Narendran N, Pearce I, Peto T, Sivaprasad S, Younis S, Napier J, Gilbert R, Ismat S.   +15 more
europepmc   +1 more source

Leucine‐rich glioma inactivated 1 (LGI1) is a ganglioside‐binding protein

FEBS Letters, EarlyView.
Neuronal hyperexcitability associated with a decrease/absence of the extracellular protein LGI1 has been suggested to be primarily due to the downregulation of Kv1 channel expression. The molecular mechanisms underlying this decrease have not yet been elucidated.
Kévin Debreux, Christian Lévêque, Fodil Azzaz, Marion Sangiardi, Sarosh R Irani, Michael Seagar, Jacques Fantini, Oussama El Far   +7 more
wiley   +1 more source

Five-year Outcome of Aflibercept Administration with “Treat and Extend” for Neovascular Age-Related Macular Degeneration

Clinical Ophthalmology
Iori Wada,1,2 Yuji Oshima,3 Yosuke Fukuda,1 Satomi Shiose,1 Kumiko Kano,1 Keijiro Ishikawa,1 Shintaro Nakao,4 Yoshihiro Kaizu,1,5 Eiichi Hasegawa,1,2 Ram Kannan,6,7 Tatsuro Ishibashi,1 Koh-Hei Sonoda1 1Department of Ophthalmology, Graduate School of ...
Wada I, Oshima Y, Fukuda Y, Shiose S, Kano K, Ishikawa K, Nakao S, Kaizu Y, Hasegawa E, Kannan R, Ishibashi T, Sonoda KH   +11 more
doaj  

A context‐dependent modulatory role for eIF6 in acquired resistance to vemurafenib in melanoma

FEBS Letters, EarlyView.
Acquired resistance to vemurafenib upregulates the translation factor eIF6 in melanoma cells. Silencing eIF6 in resistant cells reduces proliferation and partially restores drug sensitivity, whereas its overexpression increases sensitivity across melanoma lines regardless of BRAF status, via modulation of mTOR, S6K, and MAPK signaling.
George Kyriakopoulos, Antonia Petropoulou, Alexandra Anastogianni, Angelina Bania, Vassilis Stamatakis, Argyris Alexiou, Chi‐Ping Day, Glenn Merlino, Katerina Grafanaki, Constantinos Stathopoulos   +9 more
wiley   +1 more source